Adagrasib Moving Ahead in GI Cancers
Researchers reported a 100% disease control rate in 27 evaluable patients with KRASG12C-mutant pancreatic ductal adenocarcinoma and other gastrointestinal tumors, not including colorectal cancer, who received adagrasib monotherapy. These preliminary data come from the phase II portion of the KRYSTAL...
Gespeichert in:
| Veröffentlicht in: | Cancer discovery 2022-03, Vol.12 (3), p.590-591 |
|---|---|
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Zusammenfassung: | Researchers reported a 100% disease control rate in 27 evaluable patients with KRASG12C-mutant pancreatic ductal adenocarcinoma and other gastrointestinal tumors, not including colorectal cancer, who received adagrasib monotherapy. These preliminary data come from the phase II portion of the KRYSTAL-1 study, which is assessing the safety and efficacy of the KRASG12C inhibitor. |
|---|---|
| ISSN: | 2159-8274 2159-8290 |
| DOI: | 10.1158/2159-8290.CD-NB2022-0003 |